Shanghai Haohai Biological Technology Co. Ltd
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyal… Read more
Shanghai Haohai Biological Technology Co. Ltd - Asset Resilience Ratio
Shanghai Haohai Biological Technology Co. Ltd (5HB) has an Asset Resilience Ratio of 1.44% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Shanghai Haohai Biological Technology Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Haohai Biological Technology Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €103.61 Million | 1.44% |
| Total Liquid Assets | €103.61 Million | 1.44% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Haohai Biological Technology Co. Ltd maintains only 1.44% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Haohai Biological Technology Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Haohai Biological Technology Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Shanghai Haohai Biological Technology Co. Ltd (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Shanghai Haohai Biological Technology Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.23% | €87.85 Million | €7.12 Billion | +1.08pp |
| 2023-12-31 | 0.16% | €11.08 Million | €7.11 Billion | +0.06pp |
| 2022-12-31 | 0.10% | €6.75 Million | €6.89 Billion | +0.01pp |
| 2021-12-31 | 0.09% | €6.38 Million | €6.95 Billion | -0.15pp |
| 2020-12-31 | 0.24% | €15.14 Million | €6.30 Billion | -1.59pp |
| 2018-12-31 | 1.83% | €81.28 Million | €4.44 Billion | -- |